

# Label Expansion for existing approved molecules

---

**B3 Pharma** intends to expand **Paclitaxel's** label beyond its original approved use, for additional oncological therapeutic indications such as Leptomeningeal Carcinomatosis, Brain Metastases originating from Breast, Lung and Melanomas, as well as Glioblastomas that were not originally approved at the time of initial regulatory approval for Paclitaxel.

This involves updating the product's official label and prescribing information to reflect these new uses.

Following a positive interim analysis during Phase III clinical (ANG1005-CLN-07), B3 Pharma intends to update Paclitaxel's official label and prescribing information to reflect these new uses by registering ANG1005 on the National Comprehensive Cancer Network (NCCN) Guidelines.

This will enable all individuals involved in cancer care, including clinicians, payers and patients make informed decisions that will lead to optimal outcomes and help guide coverage determination